Found 15 hits Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase BTK' and Ligand = 'BDBM166011' Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Montana State University
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
J Med Chem 50: 4928-38 (2007)
BindingDB Entry DOI: 10.7270/Q2474D50 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2X06C0T |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9688629 (2017)
BindingDB Entry DOI: 10.7270/Q20863G5 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9802915 (2017)
BindingDB Entry DOI: 10.7270/Q2JW8H17 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10604504 (2020)
BindingDB Entry DOI: 10.7270/Q2H70JT2 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | n/a | n/a |
Montana State University
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
J Med Chem 50: 4928-38 (2007)
BindingDB Entry DOI: 10.7270/Q2474D50 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10604504 (2020)
BindingDB Entry DOI: 10.7270/Q2H70JT2 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| | n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2X06C0T |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9802915 (2017)
BindingDB Entry DOI: 10.7270/Q2JW8H17 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 0.240 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9688629 (2017)
BindingDB Entry DOI: 10.7270/Q20863G5 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| | n/a | n/a | 6.40 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA
| |
Citation and Details
BindingDB Entry DOI: 10.7270/Q2X06C0T |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10604504 (2020)
BindingDB Entry DOI: 10.7270/Q2H70JT2 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Montana State University
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
J Med Chem 50: 4928-38 (2007)
BindingDB Entry DOI: 10.7270/Q2474D50 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9802915 (2017)
BindingDB Entry DOI: 10.7270/Q2JW8H17 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM166011
(US10604504, Example 211 | US11623921, Example 211 ...)Show SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O |(-6.62,1.93,;-5.08,1.93,;-4.18,3.17,;-2.71,2.69,;-1.38,3.47,;-.05,2.69,;-.05,1.15,;1.29,.38,;-1.38,.38,;-1.38,-1.15,;-2.71,-1.93,;-2.71,-3.47,;-1.38,-4.23,;-.05,-3.47,;1.29,-4.23,;2.62,-3.47,;2.62,-1.93,;1.29,-1.15,;-.05,-1.93,;3.96,-4.23,;3.96,-5.78,;5.29,-3.47,;6.62,-4.23,;-2.71,1.15,;-4.18,.68,;-4.58,-.81,;-5.67,-1.9,;-4.18,-2.3,;-1.38,5,;-.05,5.78,;-2.71,5.78,)| Show InChI InChI=1S/C25H24FN3O2/c1-3-20(30)29-10-9-16-15(12-29)5-4-6-17(16)22-19(26)11-18(25(27)31)24-23(22)21(13(2)28-24)14-7-8-14/h3-6,11,14,28H,1,7-10,12H2,2H3,(H2,27,31) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 6.40 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9688629 (2017)
BindingDB Entry DOI: 10.7270/Q20863G5 |
More data for this
Ligand-Target Pair | |
Search and Browse
